Expert Interview
Discussing Hoth Therapeutics positive initial data in Phase 2a Clinical Trial CLEER-001, evaluating HT-001 for the treatment of Pruritus associated with skin toxicities caused by EGFR inhibitors
Ticker(s): HOTH- I am a highly accomplished MD dermatologist with a passion for providing top-quality patient care and advancing the field of dermatology. As a Gold Medallist in Clinical Dermatology and a member of several international organizations, including the European Academy of Dermatology and Venereal Diseases, I am committed to staying at the forefront of the latest developments and techniques in the field.
- On average, I’ve managed approximately 10–15 patients monthly with pruritus or acneiform eruptions, including those secondary to oncology treatments like EGFR inhibitors.
- Yes, I can speak to its clinical relevance, therapeutic potential, and considerations based on the Phase 2a data.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
